Printer Friendly

BioSpecifics Technologies reports Q1 2017 financial results.

M2 PHARMA-May 11, 2017-BioSpecifics Technologies reports Q1 2017 financial results

(C)2017 M2 COMMUNICATIONS

BioSpecifics Technologies Corp (NASDAQ: BSTC), a biopharmaceutical company, has reported its financial results for the first quarter of 2017.

The company reported net income of USD3.3m, equivalent to USD0.47 per basic share and USD0.46 per share on a fully diluted basis, for the first quarter ended 31 March 2017, compared to a net income of USD2.8m or USD0.40 per basic share and USD0.39 per share on a fully diluted basis, for the same period in 2016.

The firm posted total revenue for the first quarter ended 13 March 2017 at USD7.7m, compared to USD6.6m in the same period in 2016. The increase in total revenues for the quarterly period was due mainly to royalties and the mark-up on cost of goods sold revenue associated with an increase in sales of XIAFLEX for the treatment of Peyronie's disease and Dupuytren's contracture.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:May 11, 2017
Words:173
Previous Article:Impax Laboratories reports financial results for Q1 2017.
Next Article:Eli Lilly names new senior vice president of corporate affairs and communications.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters